Clinical Trial Update: Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety of combining radiation therapy with pembrolizumab (MK-3475) in patients with recurrent/metastatic head and neck cancer, rena…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Lung Cancer
• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer | Phase 1 | Status: COMPLETED